You are here

Prices & Quotes - UK Markets - Health Care Equipment & Services (4530)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Value:
Down 7,670.94
Change Today:
-126.70

Fusion Antibodies performing in line in year-to-date

By Josh White

Date: Friday 24 Sep 2021

LONDON (ShareCast) - (Sharecast News) - Antibody discovery, engineering and supply company Fusion Antibodies said on Friday that revenue growth in the current year had been consistent year-on-year, and in line with its expectations.
The AIM-traded firm, which was holding its annual general meeting, said customer enquiries for all of its services was "robust", with the 'OptiMAS' platform described as a "key element" in securing new business.

Board chair Simon Douglas said that so far in the current financial year, Fusion had received a 0.15m milestone payment as a result of a humanised antibody project, which was successfully commercialised by an unnamed key client.

"This was the first such payment received by the company, and is in line with our strategic objectives of unlocking the intrinsic value that our service offerings represent to our clients," he said.

"As at 31 March, the company had an interest in 15 client projects, six with fixed success payments and nine royalty agreements, and we will seek to add more such arrangements in the future when warranted by the company's contribution to a client project."

Douglas noted that in August, the firm entered into a commercial collaboration agreement with Eurofins Discovery, a provider of products and services to the drug discovery industry.

"Pursuant to the collaboration, Fusion will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins and onwards to their customers," he explained.

"The company's commitment to new research and development projects was maintained for this period, and 'OptiMAL' -the mammalian antibody library discovery platform - remains on track to deliver initial revenues in 2022."

At 1004 BST, shares in Fusion Antibodies were down 1.89% at 130p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Price Data

Price 7,670.94
Change Today -126.70
03-Dec-21 Close 7,670.94

Top Risers

Price Change
Feedback 0.90p +12.5%
Surgical Innovations Group 2.40p +6.7%
Open Orphan 21.00p +6.1%
Abingdon Health 30.00p +5.3%
Induction Healthcare Group 55.00p +4.8%
Genedrive 40.50p +2.3%
Omega Diagnostics Group 26.50p +1.9%
Circassia Group 37.70p +1.9%
Kromek Group 13.00p +1.0%
CareTech Holding 572.00p +0.4%

Top Fallers

Price Change
MyHealthchecked 2.45p -3.9%
Novacyt S.A. (CDI) 352.30p -3.4%
Medica Group 160.00p -3.0%
Craneware 2,400.00p -2.8%
Integrated Diagnostics Holdings $1.29 -2.6%
Diaceutics 101.00p -2.4%
Mediclinic International 291.60p -2.2%
Polarean Imaging 55.00p -1.8%
Cambridge Cognition Holdings 121.50p -1.6%
Intelligent Ultrasound Group 16.75p -1.5%